Skip to contentB
BIO-TECHNE Corp
B
TECHBIO-TECHNE Corp Q2 2024 · 10-Q
Revenue$272.60M$272.60M+0.4% vs Q2 2023 Net Income$27.47M$27.47M−45.1% vs Q2 2023 EPS Diluted$0.17$0.17−45.2% vs Q2 2023 Gross Profit$176,587,000−3.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BIO-TECHNE Corp · CIK 842023 · Engraved from SEC EDGAR
Operating Cash Flowderived$83,116,000+29.1% Free Cash Flowderived$68,252,000+17.1% Margins · derivedGross margin64.8%−2.7 pt vs Q2 2023
Operating margin13.9%−11.1 pt vs Q2 2023
Net margin10.1%−8.3 pt vs Q2 2023
ended Dec 31, 2023 · filed Feb 7, 2024 · 38 d after period end